Suppr超能文献

将生活质量纳入接受免疫治疗的癌症患者护理路径:对一个在线患者社区的经历和期望进行描述性横断面调查。

Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.

作者信息

Wilczynski Ophélie, Boisbouvier Anthony, Radoszycki Lise, Cotté François-Emery, Gaudin Anne-Françoise, Lemasson Hervé

机构信息

Carenity, Paris, France.

Bristol-Myers Squibb France, Rueil-Malmaison, France.

出版信息

J Med Internet Res. 2022 Jan 11;24(1):e25792. doi: 10.2196/25792.

Abstract

BACKGROUND

New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented.

OBJECTIVE

This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management.

METHODS

This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed.

RESULTS

Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient's initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss.

CONCLUSIONS

With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed.

摘要

背景

新型癌症治疗方法,如免疫检查点抑制剂(ICI),可提高癌症患者的生存率和健康相关生活质量(HRQoL)。尽管长期监测HRQoL已被证明可提高生存率,但将HRQoL纳入日常临床实践的相关记录仍然很少。

目的

本研究描述了接受ICI治疗的患者在癌症管理中与医护人员(HCP)讨论HRQoL的经历和期望。

方法

这项横断面研究在法国的一个在线患者社区(Carenity)中进行。2018年9月至2019年1月期间接受ICI治疗的癌症患者完成了一份问卷,以评估HCP在HRQoL讨论中的参与情况,以及讨论的时间和内容。

结果

纳入的82例患者(平均年龄:56.9岁,95%CI 54.2-59.6;46例[56%]为男性;34例[41%]患有肺癌)中,62例(76%)报告至少与HCP讨论过一次HRQoL,主要是全科医生(54/82,66%)、肿瘤学家(53/82,65%)和医院护士(50/82,61%)。约一半(45/82,55%)的患者对这些讨论感到满意。与肿瘤学家的讨论由患者主动发起(34/53,64%)。讨论主要发生在随访期间(40/62,65%)、出现不良事件时(30/62,48%)和治疗开始时(27/62,32%)。讨论最多的方面是症状(48/62,77%)和身体健康(43/62,69%)。关于期望,54/82(66%)的患者认为肿瘤学家是讨论HRQoL最重要的HCP。在整个护理过程中都需要进行这些讨论,特别是在诊断时(63/82,77%)、治疗开始时(75/82,92%)或治疗改变时(68/82,83%)。所有HRQoL方面都被认为有必要进行讨论。

结论

由于只有约一半的患者对HRQoL讨论感到满意,因此在临床实践中有效整合HRQoL至关重要。患者认为,这种整合应主要涉及肿瘤学家和全科医生,应在护理过程的每一步进行,并应扩展到目前很少涉及的方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba68/8790682/267f5f2c33da/jmir_v24i1e25792_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验